MedTrace Logo

Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies

NCT03654612 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-10-18

No results posted yet for this study

Summary

This open, single-arm, exploratory study looked at the efficacy and safety of apatinib in combination with S-1 as second-line treatment of advanced head and neck malignancies.

Conditions

Interventions

DRUG

Apatinib

Apatinib 500mg qd plus S-1 50mg bid d1-d14/28d cycle

Sponsors & Collaborators

  • Chinese Society of Clinical Oncology

    collaborator OTHER

  • China International Medical Foundation

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-16
Primary Completion
2020-03-01
Completion
2021-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03654612 on ClinicalTrials.gov